Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
批准号:
10738337
负责人:
NABEEL El-BARDEESY
金额:
$23.38万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-19 至 2024-01-31
关键词:
AddressAdultAutomobile DrivingBindingBiologicalBiological AssayBiological MarkersBiological ModelsBiologyBloodCell Differentiation processCell ReprogrammingCell SeparationCell physiologyCellsCellular Metabolic ProcessCharacteristicsChromatinClinicalCredentialingDNA RepairDataDependenceDetectionDevelopmental GeneDiagnosticDifferentiation and GrowthDiseaseEarly DiagnosisEpigenetic ProcessExcisionFoundationsGenesGenetic TranscriptionGenetically Engineered MouseGlycolysisGrowthHMGA2 geneHumanIn VitroInvadedLinkMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMessenger RNAMetabolicMetabolismMethodsMicroRNAsModelingMolecularMusNeoplasm Circulating CellsNeoplasm MetastasisNonmetastaticOperative Surgical ProceduresOrganoidsOutcomePancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPatientsPhenotypePrimary NeoplasmProgression-Free SurvivalsProteomicsRNARNA-Binding ProteinsRecurrent diseaseRegulator GenesRelapseResectableRoleSamplingSiteSomatic CellSpecimenTestingTissuesTumor Suppressor ProteinsTumor TissueUndifferentiatedWorkchemotherapyclinical biomarkersdata integrationdisease natural historyearly detection biomarkersexperimental studyfetalgene networkgenetic manipulationhistone demethylaseimplantationin vivoloss of functionmigrationmouse modelneoplastic cellnoveloncofetal antigenpancreatic cancer patientspancreatic ductal adenocarcinoma modelpluripotencypredictive markerprogenitorprogramspromoterrecruitself-renewalsingle cell analysisstem cell genestranscriptome sequencingtumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Pancreatic ductal adenocarcinoma (PDA) is among the most lethal of all human malignancies. A key
clinical challenge is the propensity of these tumors for early invasion and metastasis. Thus, most patients are
not eligible for resection, and those who are often show recurrent disease. This challenge is compounded by
the absence of methods for early detection of invasive disease and incomplete understanding of the
mechanisms for PDA progression. Our discovery of the fetal RNA-binding protein Lin28b as a major
driver in PDA metastasis provides a framework to address these critical issues in this multiple-PI
proposal. In previous studies, we have found that the oncofetal RNA-binding protein Lin28b is highly
upregulated in PDA, both in murine models and human patient samples. Furthermore, new preliminary data
indicate that Lin28b is specifically upregulated in Circulating Tumor Cells (CTCs) obtained from patients with
early resectable PDA. Based on these findings, we hypothesize that Lin28b drives PDA progression and
metastasis by reprogramming cell differentiation toward a more primitive progenitor-like state, and that
detection of Lin28b in CTCs can serve as a molecular beacon for disease aggressiveness.In order to
test this hypothesis, we will: 1- Characterize Lin28b as a driver of self renewal and tumor progression in human
and murine PDA models. We will take advantage of ex-vivo grown organoids from human CTCs and specific
genetically engineered mouse models of PDA to genetically manipulate Lin28b and determine tumor
propagating cell function and ability to drive PDA progression. 2- Determine the mechanisms through which
Lin28b could drive agressiveness, exploring its downstream targets (linked to the microRNA let-7), and the
biological and metabolic features driven by this oncofetal protein. 3- Evaluate Lin28b as a predictive biomarker
of PDA early disease recurrence, taking advantage of CTCs isolated from human patients undergoing surgical
resection.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma.
准间充质表型预测胰腺导管腺癌的全身转移。
DOI:
10.1038/s41379-018-0196-2
发表时间:
2019
期刊:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
影响因子:
--
作者:
[Mahadevan,KrishnanK, Arora,KshitijS, Amzallag,Arnaud, Williams,Erik, Kulkarni,AnupriyaS, Fernandez-DelCastillo,Carlos, Lillemoe,KeithD, Bardeesy,Nabeel, Hong,TheodoreS, Ferrone,CristinaR, Ting,DavidT, Deshpande,Vikram]
通讯作者:
Deshpande,Vikram
Functions of mutant IDH in cholangiocarcinoma
-
批准号:10800231
-
项目类别:
-
资助金额:$65.35万
-
财政年份:2023
-
负责人:NABEEL El-BARDEESY
-
依托单位:
2023 Pancreatic Diseases Gordon Research Conference and Gordon Research Seminar
-
批准号:10681581
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2023
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10558954
-
项目类别:
-
资助金额:$12.77万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10338071
-
项目类别:
-
资助金额:$56.26万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10559707
-
项目类别:
-
资助金额:$56.26万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
-
批准号:10443802
-
项目类别:
-
资助金额:$66.39万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
-
批准号:10524240
-
项目类别:
-
资助金额:$11.65万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
-
批准号:10337194
-
项目类别:
-
资助金额:$47.06万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
-
批准号:10083201
-
项目类别:
-
资助金额:$59.91万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
-
批准号:10208803
-
项目类别:
-
资助金额:$67.74万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigentics
-
批准号:10026739
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:8234112
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:8437129
-
项目类别:
-
资助金额:$32.6万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:7937156
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:8100370
-
项目类别:
-
资助金额:$34.61万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:8137997
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:8517597
-
项目类别:
-
资助金额:$32.61万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:7895069
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:8305030
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:7690358
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
海外基金